ArticlePloS one2014
Characterization of desmoglein expression in the normal prostatic gland. Desmoglein 2 is an independent prognostic factor for aggressive prostate cancer.
Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it, 56 citations in OpenAlex.
- Pooled it
- Exploring Biomarkers Related to Cell Adhesion in Polycystic Ovary Syndrome Using Bioinformatics and Conducting Experimental Validation.International journal of general medicine · 2025Article
- Telomere-related prognostic biomarkers for survival assessments in pancreatic cancer.Scientific reports · 2023Article
- Downregulation of desmoglein 2 promotes EMT progression in gallbladder cancer.Histology and histopathology · 2023Article
- Oncolytic adenovirus coding for bispecific T cell engager against human MUC-1 potentiates T cell response against solid tumors.Molecular therapy oncolytics · 2023Article
- Desmoglein-2 as a cancer modulator: friend or foe?Frontiers in oncology · 2023Review
- Prognostic utility of the ovarian cancer secretome: a systematic investigation.Archives of gynecology and obstetrics · 2022Review
- Article
- Expansion of mouse castration-resistant intermediate prostate stem cells in vitro.Stem cell research & therapy · 2022Article
- Multigene Profiling of Circulating Tumor Cells (CTCs) for Prognostic Assessment in Treatment-Naïve Metastatic Hormone-Sensitive Prostate Cancer (mHSPC).International journal of molecular sciences · 2021Article
- Loss of desmoglein-2 promotes gallbladder carcinoma progression and resistance to EGFR-targeted therapy through Src kinase activation.Cell death and differentiation · 2021Article
- Interplay between desmoglein2 and hypoxia controls metastasis in breast cancer.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- DSG2 expression is low in colon cancer and correlates with poor survival.BMC gastroenterology · 2021Article
- Desmoglein-2 as a prognostic and biomarker in ovarian cancer.Cancer biology & therapy · 2020Article
- Adenovirus Receptor Expression in Cancer and Its Multifaceted Role in Oncolytic Adenovirus Therapy.International journal of molecular sciences · 2020Review
- Significance of desmoglein-2 on cell malignant behaviors via mediating MAPK signaling in cervical cancer.The Kaohsiung journal of medical sciences · 2020Article
- The molecular function of kallikrein-related peptidase 14 demonstrates a key modulatory role in advanced prostate cancer.Molecular oncology · 2020Article
- Article
- A Five-Genes-Based Prognostic Signature for Cervical Cancer Overall Survival Prediction.International journal of genomics · 2020Article
- Extracellular vesicles provide a capsid-free vector for oncolytic adenoviral DNA delivery.Journal of extracellular vesicles · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
purposeThe expression of desmogleins (DSGs), which are known to be crucial for establishing and maintaining the cell-cell adhesion required for tissue integrity, has been well characterized in the epidermis and hair follicle; however, their expression in other epithelial tissues such as prostate is poorly understood. Although downregulation of classical cadherins, such as E-cadherin, has been described in prostate cancer tissue samples, the expression of desmogleins has only been previously reported in prostate cancer cell lines. In this study we characterized desmoglein expression in normal prostate tissues, and further investigated whether Desmoglein 2 (DSG2) expression specifically can serve as a potential clinical prognostic factor for patients diagnosed with primary prostate cancer. EXPERIMENTAL
designWe utilized immunofluorescence to examine DSG2 expression in normal prostate (n = 50) and in a clinically well-characterized cohort of prostate cancer patients (n = 414). Correlation of DSG2 expression with clinico-pathological characteristics and biochemical recurrence was analyzed to assess its clinical significance.
resultsThese studies revealed that DSG2 and DSG4 were specifically expressed in prostatic luminal cells, whereas basal cells lack their expression. In contrast, DSG1 and DSG3 were not expressed in normal prostate epithelium. Further analyses of DSG2 expression in prostate cancer revealed that reduced levels of this biomarker were a significant independent marker of poor clinical outcome.
conclusionHere we report for the first time that a low DSG2 expression phenotype is a useful prognostic biomarker of tumor aggressiveness and may serve as an aid in identifying patients with clinically significant prostate cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.